Stock 688180 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Shanghai Junshi Biosciences Co., Ltd. Shanghai S.E.

Equities

688180

CNE1000041Z1

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 15/05/2024 BST 		5-day change 1st Jan Change
30.27 CNY -0.20% Intraday chart for Shanghai Junshi Biosciences Co., Ltd. -1.72% -27.64%
04-29 Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-25 Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab MT

Business Summary

Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases . The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.

Number of employees: 2,568

Sales per Business

HKD in Million2022Weight2023Weight Delta
Innovative Drugs
100.0 %
1,690 100.0 % 1,660 100.0 % -1.77%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
78.8 %
875 61.2 % 1,284 78.8 % +46.70%
Overseas
21.2 %
554 38.8 % 345 21.2 % -37.78%

Managers

Managers TitleAgeSince
Jianjun Zou CEO
 Chief Executive Officer 52 19/04/22
Zhuo Bing Zhang FOU
 Founder 57 26/12/12
Cong Li CEO
 Chief Executive Officer 60 21/12/16
Bao Hong Xu DFI
 Director of Finance/CFO 45 31/10/20
Jun Xiong CHM
 Chairman 50 26/03/15
Patricia Keegan CTO
 Chief Tech/Sci/R&D Officer - -
Gang Wang BRD
 Director/Board Member 67 28/08/19
Ning Li BRD
 Director/Board Member 63 07/01/18
Sheng Yao BRD
 Director/Board Member 49 31/05/14
Hui Feng BRD
 Director/Board Member 48 31/12/13

Members of the board

Members of the board TitleAgeSince
Roy Herbst BRD
 Director/Board Member 60 23/06/18
Cong Li CEO
 Chief Executive Officer 60 21/12/16
Yi Tang BRD
 Director/Board Member 56 29/05/15
Jun Xiong CHM
 Chairman 50 26/03/15
Hui Feng BRD
 Director/Board Member 48 31/12/13
Sheng Yao BRD
 Director/Board Member 49 31/05/14
Zhuo Bing Zhang FOU
 Founder 57 26/12/12
Ning Li BRD
 Director/Board Member 63 07/01/18
Xiao Yuan Feng BRD
 Director/Board Member 68 15/12/21
An Ming Meng BRD
 Director/Board Member 61 29/06/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 766,394,171 0 679,027 ( 0.0886 %) 15.17 %
Stock B 1 219,295,700 149,560,900 ( 68.20 %) 0

Shareholders

NameEquities%Valuation
GREENLAND HOLDINGS CORPORATION LIMITED
23.43 %
51,386,400 23.43 % 77 M ¥
GIC Pte Ltd. (Investment Management)
6.997 %
15,344,289 6.997 % 23 M ¥
Loyal Valley Capital Co. Ltd.
5.891 %
12,918,902 5.891 % 19 M ¥
HHLR Advisors Ltd.
5.198 %
11,400,000 5.198 % 17 M ¥
UBS Asset Management (Hong Kong) Ltd.
1.426 %
3,128,000 1.426 % 5 M ¥
China Asset Management Co., Ltd.
0.7551 %
1,656,000 0.7551 % 2 M ¥
Bosera Asset Management Co., Ltd.
0.5847 %
1,282,200 0.5847 % 2 M ¥
Fullgoal Fund Management Co., Ltd.
0.3364 %
737,800 0.3364 % 1 M ¥
Value Partners Ltd.
0.2317 %
508,000 0.2317 % 763 834 ¥
State Street Global Advisors Ltd.
0.1598 %
350,492 0.1598 % 527 003 ¥
NameEquities%Valuation
Jun Xiong
20.42 %
88,355,068 20.42 % 368 M ¥
Loyal Valley Capital Co. Ltd.
18.23 %
78,852,000 18.23 % 328 M ¥
Shenzhen Qianhai Yuanben Equity Investment Fund Management Co.
11.14 %
48,184,000 11.14 % 201 M ¥
Feng Xiang Xiong
9.491 %
41,060,000 9.491 % 171 M ¥
China Asset Management Co., Ltd.
6.497 %
28,105,380 6.497 % 117 M ¥
Yu Qing Zhou
5.012 %
21,680,800 5.012 % 90 M ¥
Hui Feng
3.047 %
13,180,000 3.047 % 55 M ¥
Zhen Hua Wang
2.545 %
11,010,194 2.545 % 46 M ¥
Wen Shi
2.545 %
11,010,194 2.545 % 46 M ¥
UBS Asset Management Switzerland AG
2.382 %
10,305,838 2.382 % 43 M ¥

Holdings

NameEquities%Valuation
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
0.46%
 2,000,000 0.46% 8,324,240 $

Company contact information

Shanghai Junshi Biosciences Co., Ltd.

13th Floor, Building 2 No. 36 & 58 Haiqu Road

201203, Shanghai

+

http://www.junshipharma.com
address Shanghai Junshi Biosciences Co., Ltd.(688180)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Shanghai Junshi Biosciences Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
12.75 CNY
Average target price
22.86 CNY
Spread / Average Target
+79.27%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
-2.32% 92.59B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.16% 41.43B
BIOGEN INC. Stock Biogen Inc.
-11.10% 33.49B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-20.19% 14.62B
INCYTE CORPORATION Stock Incyte Corporation
-9.41% 12.77B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.25% 11.58B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.00% 11.35B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.49% 8.97B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-6.32% 8.3B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 1877 Stock
  4. 688180 Stock
  5. Company Shanghai Junshi Biosciences Co., Ltd.